temozolomide

temozolomide is an oral alkylating agent chemotherapy drug used primarily in the treatment of aggressive brain tumors. It is a standard first-line therapy for glioblastoma multiforme, often administered concurrently with radiotherapy in a regimen known as the Stupp protocol. The drug is also used for treating anaplastic astrocytoma and certain metastatic melanoma cases, demonstrating its role in neuro-oncology.

Medical uses

Temozolomide is a cornerstone in the management of high-grade gliomas, most notably newly diagnosed glioblastoma, where it is combined with focal radiation therapy. This combination, established by the landmark trial led by Roger Stupp, significantly improves overall survival compared to radiation alone. It is also indicated for recurrent glioblastoma and anaplastic astrocytoma following prior therapy with a nitrosourea and procarbazine. Beyond central nervous system tumors, it has activity against advanced metastatic melanoma, often in combination with dacarbazine, and is being investigated in other malignancies like neuroendocrine tumors and certain leukemias. Treatment schedules, such as the standard 5-day regimen or the dose-dense "metronomic" schedule, are tailored based on O6-methylguanine-DNA methyltransferase promoter methylation status, a key biomarker predictive of response.

Adverse effects

The most common adverse effects of temozolomide are related to myelosuppression, including thrombocytopenia, neutropenia, and leukopenia, which are dose-limiting and require regular monitoring of complete blood count. Significant nausea and vomiting are frequent but are often well-managed with prophylactic antiemetics like ondansetron. Other reported effects include constipation, headache, fatigue, alopecia, and anorexia. Serious but less common risks include opportunistic infections such as Pneumocystis jirovecii pneumonia, leading to the recommendation for prophylaxis with trimethoprim/sulfamethoxazole during prolonged dosing schedules. Hepatotoxicity, manifesting as elevated transaminase levels, and rare cases of severe interstitial lung disease have also been documented.

Pharmacology

Temozolomide is a prodrug that undergoes rapid non-enzymatic conversion at physiological pH to its active metabolite, MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). This active compound exerts its cytotoxic effect by functioning as an alkylating agent, transferring a methyl group to specific sites on DNA, most critically the O6 position of guanine. This DNA adduct formation leads to mismatch repair system failure and ultimately triggers apoptosis in tumor cells. Its ability to cross the blood-brain barrier is a critical pharmacological feature for treating brain tumors. Resistance is strongly associated with high levels of the DNA repair protein MGMT, which removes the lethal methyl adducts; epigenetic silencing of the MGMT gene via promoter methylation is a favorable prognostic factor.

Chemistry

Temozolomide is chemically described as 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d] [1,2,3,5]tetrazine-8-carboxamide. It is an imidazotetrazine derivative, a stable prodrug analog of the older compound dacarbazine. The molecule is stable under acidic conditions but undergoes rapid hydrolysis in basic media to release MTIC. It is a white to light tan/light pink powder with a molecular formula of C₆H₆N₆O₂ and is sparingly soluble in water. Its synthesis and stability profile were pivotal in enabling its development as an oral chemotherapeutic agent.

History

Temozolomide was synthesized in the early 1980s by researchers including Malcolm Stevens and his team at Aston University in Birmingham, United Kingdom. It was developed as a more stable, orally bioavailable alternative to dacarbazine, designed to treat malignant glioma. The drug received its first approval from the Medicines and Healthcare products Regulatory Agency in the UK in 1999 and later from the U.S. Food and Drug Administration in 2005 for glioblastoma multiforme, following the pivotal clinical trial results published in the New England Journal of Medicine. The establishment of the Stupp protocol by Roger Stupp and colleagues at the European Organisation for Research and Treatment of Cancer fundamentally changed the standard of care for this disease.

Category:Antineoplastic drugs Category:Imidazoles Category:Tetrazines